CYTK

Cytokinetics, Incorporated

Phase 3 Confirmed

aficamten

non-obstructive hypertrophic cardiomyopathy

Resolved

63days ago

Phase 3 readout · May 5, 2026

What's at stake Phase 3 trial results for aficamten in non-obstructive hypertrophic cardiomyopathy are due May 5, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 15h ago

“Report topline results from ACACIA-HCM in Q2 2026.”

Add to calendar Post on X Reddit

Provenance

2 sources on file.

SEC 8-K — verified 15h ago
SEC 8-K — verified 16h ago

Link copied ✓